Additional mutations affect consensus cancer genes (CDKN2A, IDH2, TP53) as well as tumor suppressors previously identified in cutaneous T cell lymphoma (TNFAIP3, FAS, PDCD1). This evidence concerns the gene CDKN2A and primary cutaneous T-cell non-Hodgkin lymphoma.